Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

Stock Information for Hemostemix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Hemostemix Inc.

Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.